Tianyin Pharmaceutical Co., Inc. (TPI) Receives Chinese SFDA New Product Approvals for 2 Generic Products

CHENGDU, China, Dec. 1, 2009 (PRNewswire-Asia-FirstCall) — Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a manufacturer and supplier of modernized traditional Chinese medicine (“TCM”) based in Chengdu, China, today announced that it has received approvals from the Chinese State Food and Drug Administration (SFDA) to produce Pediatric Fever and Cough Oral Liquid in dosage form of 10 ml/tube (SFDA approval number Z20093060) and Antibacterial and Anti-inflammatory Capsules in dosage form of 0.27 gram/capsule (SFDA approval number Z20090855).

Pediatric Fever and Cough Oral Liquid is a generic prescription TCM that is used for respiratory tract infections and influenza of children to effectively reduce symptoms such as fever, shakes, cough, phlem, shortness of breath, dry mouth and sore throat. According to Tianyin’s market research and estimation, annual sales of this type of products are approximately $1.1 billion in China. Tianyin expects the demand of this product will increase during the wintertime flu season and that our introduction of this product will increase the Company’s market share in the pediatric medicine market.

Antibacterial and Anti-inflammatory Capsules is a generic OTC TCM which is used mainly as natural antibiotics to treat bacterial infection and inflammation. It has minimal side effects when compared to western antibiotics. Tianyin estimates that total annual sales of antibacterial and anti-inflammatory products are approximately $1.5 billion in China. Tianyin expects to gain a portion of the market share in antibiotics medicine through the production and marketing of Antibacterial and Anti-inflammatory Capsules. The product will be manufactured in Company’s new production facility.

“We are very pleased to receive approvals for our Pediatric Fever and Cough Oral Liquid and Antibacterial and Anti-inflammatory Capsules from the Chinese SFDA. One of our key growth strategies is to further expand our portfolio,” Dr. Guoqing Jiang, Chairman and CEO of Tianyin Pharmaceutical Co., Inc., commented. “These products further complement our product portfolio and create additional revenue opportunities for indications which we have not previously addressed. We will immediately leverage current distribution network and available production capacity to produce these two products.”

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine (“TCM”) in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 39 products, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 17 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission.